Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies
{{output}}
Background & aims: Bulevirtide (BLV) is a first-in-class entry inhibitor and the only approved treatment for patients chronically infected with HDV in Europe. We aimed to investigate the efficacy of BLV treatment in paired liver ... ...
